Improvements were seen in 17 of 21 clinical indexes ( 81.0 % ) in both interventions , including the primary outcome variables asthma control ( d = 0.81 ) , peak flow variability ( d = 0.54 ) , quality of life , bronchodilator use , lung function , and airway hyperreactivity .